Loading...
•
Mar 31
Amneal Q1 2025 Earnings Report
Amneal Pharmaceuticals, Inc. reported its financial results for the first quarter ended March 31, 2025, showing an increase in net revenue, net income, and adjusted EBITDA compared to the same period last year.
Key Takeaways
Amneal Pharmaceuticals, Inc. delivered a strong first quarter in 2025, with broad-based growth across all three segments. Net revenue increased by 5% to $695 million, and net income attributable to Amneal Pharmaceuticals, Inc. was $12 million, a significant improvement from a net loss in the prior year. Adjusted EBITDA also saw a 12% increase, reaching $170 million.
Net revenue for Q1 2025 increased 5% to $695 million, up from $659 million in Q1 2024.
Net income attributable to Amneal Pharmaceuticals, Inc. was $12 million in Q1 2025, a substantial improvement from a net loss of $92 million in Q1 2024.
Adjusted EBITDA increased 12% to $170 million in Q1 2025, driven by strong revenue performance and improved gross margin.
Diluted income per share was $0.04 in Q1 2025, compared to a diluted loss per share of $0.30 in Q1 2024.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal Pharmaceuticals, Inc. affirmed its previously provided full year 2025 guidance, expecting net revenue between $3.0 billion and $3.1 billion, adjusted EBITDA between $650 million and $675 million, and adjusted diluted EPS between $0.65 and $0.70.
Positive Outlook
- Affirming full year 2025 guidance indicates confidence in continued strong performance.
- Expected net revenue of $3.0 billion - $3.1 billion suggests continued growth.
- Anticipated adjusted EBITDA of $650 million - $675 million points to strong profitability.
- Projected adjusted diluted EPS of $0.65 - $0.70 indicates healthy earnings per share.
- Management's confidence in delivering sustainable growth and value creation for stakeholders.
Challenges Ahead
- Guidance is based on current expectations and subject to market conditions and other factors.
- Future product launches and their timing could impact actual results.
- Costs incurred and benefits realized from restructuring activities are subject to change.
- Uncertainty regarding acquisition-related expenses, asset impairments, and legal settlements.
- The company cannot provide a reconciliation between non-GAAP projections and GAAP measures due to inherent uncertainties.
Revenue & Expenses
Visualization of income flow from segment revenue to net income